高风险处方增加全髋关节置换术后新发持续阿片类药物使用
该回顾性分析基于密歇根州Medicare索赔数据,纳入2013至2016年行全髋关节置换术(THA)的骨科医生及其阿片类药物初治患者(年龄>65岁)。结果显示,66%的诊疗 encounters 存在高风险处方;初始处方量第三四分位(aOR 2.91,95%CI 1.53-5.51)和30天处方剂量第四四分位(aOR 1.93,95%CI 1.03-3.61)与持续使用风险增加相关。
要点
- 医生高风险处方行为与THA术后新发持续阿片使用独立相关。
- 初始处方量位于第三四分位者持续使用风险显著增高(aOR 2.91)。
- 30天处方剂量位于最高四分位者风险亦增高(aOR 1.93)。
核心结论
- 术后持续阿片使用是多因素所致,但医生处方模式起重要作用;减少处方并鼓励替代方案可能降低持续使用。
研究设计与样本
- 回顾性分析密歇根州Medicare索赔数据,纳入2013至2016年行THA的骨科医生及其阿片初治、年龄>65岁患者,采用多水平分层logistic回归。
主要发现
- 医生在66%的诊疗 encounters 中实施高风险处方。
- 初始处方量第三四分位组aOR为2.91(95%CI 1.53-5.51)。
- 30天处方剂量第四四分位组aOR为1.93(95%CI 1.03-3.61)。
临床怎么用
- 骨科医生应避免高风险阿片处方模式,如高日剂量、重叠苯二氮卓类、多提供者处方或长效阿片。
- 关注初始处方量和30天处方剂量,尽量采用低剂量并鼓励非阿片替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association between surgeon prescribing practices and new persistent postoperative opioid use is not well understood. We examined the association between surgeon prescribing and new persistent use among total hip arthroplasty (THA) patients. METHODS: A retrospective analysis of Medicare claims in Michigan was performed. The study cohort consisted of orthopedic surgeons performing THAs from 2013 to 2016 and their opioid-naïve patients, aged >65 years. High-risk prescribing included high daily doses, overlapping benzodiazepine prescriptions, concurrent opioid prescriptions, prescriptions from multiple providers, or long-acting opioid prescriptions. The occurrence of a preoperative prescription, initial prescription size, and 30-day prescription dosage were examined as individual exposures. Surgeons were categorized into quartiles by prescribing practices, and multilevel hierarchical logistic regression was used to examine associations with postoperative new persistent opioid use. RESULTS: Surgeons exhibited high-risk prescribing for 66% of encounters. Patients of surgeons with the highest rates of high-risk prescribing were more likely to develop persistent use compared with patients of surgeons with the lowest rates (adjusted rates: 9.7% vs 4.6%, P = .011). Patients of surgeons with initial prescription sizes in the "high" (third) quartile (adjusted odds ratio, 2.91; 95% confidence interval, 1.53-5.51), and of surgeons in the "highest" (fourth) quartile of 30-day prescription dosage (adjusted odds ratio, 1.93; 95% confidence interval, 1.03-3.61), were more likely to develop persistent opioid use compared with patients of surgeons with low initial and 30-day prescription sizes, respectively. CONCLUSION: The development of persistent opioid use after surgery is multifactorial, and surgeon prescribing patterns play an important role. Reducing prescribing and encouraging opioid alternatives could minimize postoperative persistent opioid use.
引用
- Delaney LD, Gunaseelan V, Rieck H, et al. High-Risk Prescribing Increases Rates of New Persistent Opioid Use in Total Hip Arthroplasty Patients. J Arthroplasty. 2020. PMID: 32389404. doi:10.1016/j.arth.2020.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。